MedTrace Logo

Study in Chronic Kidney Disease (CKD) Not on Dialysis

NCT01110629 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 143

Last updated 2014-10-15

No results posted yet for this study

Summary

The objective of this study is to investigate the efficacy and safety of lanthanum carbonate 750 to 2,250 mg in Japanese Chronic Kidney Disease Stage 3, 4 and 5 subjects not on dialysis.

Conditions

  • Hyperphosphatemia

Interventions

DRUG

Fosrenol (Lanthanum Carbonate, BAY77-1931)

Daily dose: 750-2250mg 3 times a dayfor 8 weeks.

DRUG

Placebo

daily dose: 3 tablets TID for 8 weeks.

Sponsors & Collaborators

  • Shire

    collaborator INDUSTRY

  • Bayer

    lead INDUSTRY

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01110629 on ClinicalTrials.gov